174 related articles for article (PubMed ID: 35247901)
21. CD147 confers temozolomide resistance of glioma cells via the regulation of β-TrCP/Nrf2 pathway.
Bu X; Qu X; Guo K; Meng X; Yang X; Huang Q; Dou W; Feng L; Wei X; Gao J; Sun W; Chao M; Han L; Hu Y; Shen L; Zhang J; Wang L
Int J Biol Sci; 2021; 17(12):3013-3023. PubMed ID: 34421346
[No Abstract] [Full Text] [Related]
22. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
23. Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model.
Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats TS
Cancer Biol Ther; 2009 Oct; 8(20):1924-33. PubMed ID: 19738431
[TBL] [Abstract][Full Text] [Related]
24. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
[TBL] [Abstract][Full Text] [Related]
25. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
[TBL] [Abstract][Full Text] [Related]
26. DHFR/TYMS are positive regulators of glioma cell growth and modulate chemo-sensitivity to temozolomide.
Zhao M; Tan B; Dai X; Shao Y; He Q; Yang B; Wang J; Weng Q
Eur J Pharmacol; 2019 Nov; 863():172665. PubMed ID: 31542479
[TBL] [Abstract][Full Text] [Related]
27. Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells.
Ryu CH; Yoon WS; Park KY; Kim SM; Lim JY; Woo JS; Jeong CH; Hou Y; Jeun SS
J Biomed Biotechnol; 2012; 2012():987495. PubMed ID: 22701311
[TBL] [Abstract][Full Text] [Related]
28. Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas.
Minea RO; Duc TC; Swenson SD; Cho HY; Huang M; Hartman H; Hofman FM; Schönthal AH; Chen TC
PLoS One; 2020; 15(9):e0238238. PubMed ID: 32881880
[TBL] [Abstract][Full Text] [Related]
29. Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide.
López-Valero I; Saiz-Ladera C; Torres S; Hernández-Tiedra S; García-Taboada E; Rodríguez-Fornés F; Barba M; Dávila D; Salvador-Tormo N; Guzmán M; Sepúlveda JM; Sánchez-Gómez P; Lorente M; Velasco G
Biochem Pharmacol; 2018 Nov; 157():266-274. PubMed ID: 30195736
[TBL] [Abstract][Full Text] [Related]
30. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
Kim SM; Woo JS; Jeong CH; Ryu CH; Jang JD; Jeun SS
Stem Cells Transl Med; 2014 Feb; 3(2):172-82. PubMed ID: 24436439
[TBL] [Abstract][Full Text] [Related]
31. PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide.
Higuchi F; Fink AL; Kiyokawa J; Miller JJ; Koerner MVA; Cahill DP; Wakimoto H
Mol Cancer Ther; 2018 Dec; 17(12):2551-2563. PubMed ID: 30217967
[TBL] [Abstract][Full Text] [Related]
32. From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas.
Sun X; Turcan S
Cells; 2021 May; 10(5):. PubMed ID: 34067729
[TBL] [Abstract][Full Text] [Related]
33. Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain.
Oliva CR; Nozell SE; Diers A; McClugage SG; Sarkaria JN; Markert JM; Darley-Usmar VM; Bailey SM; Gillespie GY; Landar A; Griguer CE
J Biol Chem; 2010 Dec; 285(51):39759-67. PubMed ID: 20870728
[TBL] [Abstract][Full Text] [Related]
34. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
[TBL] [Abstract][Full Text] [Related]
35. Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier.
Albanese C; Alzani R; Amboldi N; Degrassi A; Festuccia C; Fiorentini F; Gravina G; Mercurio C; Pastori W; Brasca M; Pesenti E; Galvani A; Ciomei M
Br J Pharmacol; 2013 May; 169(1):156-66. PubMed ID: 23347136
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas.
Ulasov I; Thaci B; Sarvaiya P; Yi R; Guo D; Auffinger B; Pytel P; Zhang L; Kim CK; Borovjagin A; Dey M; Han Y; Baryshnikov AY; Lesniak MS
Cancer Med; 2013 Aug; 2(4):457-67. PubMed ID: 24156018
[TBL] [Abstract][Full Text] [Related]
37. The temozolomide derivative 2T-P400 inhibits glioma growth via administration route of intravenous injection.
Li R; Tang D; Zhang J; Wu J; Wang L; Dong J
J Neurooncol; 2014 Jan; 116(1):25-30. PubMed ID: 24065569
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
[TBL] [Abstract][Full Text] [Related]
39. Knockdown ATG4C inhibits gliomas progression and promotes temozolomide chemosensitivity by suppressing autophagic flux.
Wen ZP; Zeng WJ; Chen YH; Li H; Wang JY; Cheng Q; Yu J; Zhou HH; Liu ZZ; Xiao J; Chen XP
J Exp Clin Cancer Res; 2019 Jul; 38(1):298. PubMed ID: 31291988
[TBL] [Abstract][Full Text] [Related]
40. ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts.
Yuan AL; Ricks CB; Bohm AK; Lun X; Maxwell L; Safdar S; Bukhari S; Gerber A; Sayeed W; Bering EA; Pedersen H; Chan JA; Shen Y; Marra M; Kaplan DR; Mason W; Goodman LD; Ezhilarasan R; Kaufmann AB; Cabral M; Robbins SM; Senger DL; Cahill DP; Sulman EP; Cairncross JG; Blough MD
PLoS One; 2018; 13(8):e0202860. PubMed ID: 30153289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
